Hologic vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (77 vs 80)
Hologic logo

Hologic

LeaderHealthcare Tech

Enterprise

Women's health medtech with $3.9B FY2024 revenue; 3D Genius Mammography market leader; Panther molecular diagnostics platform; annual screening guidelines expand mammography TAM by ~30%.

AI VisibilityBeta
Overall Score
B77
Category Rank
#53 of 596
AI Consensus
82%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
75
Gemini
77

About

Hologic is a global medical technology company uniquely dedicated to women's health, founded in 1985 and headquartered in Marlborough, Massachusetts, trading on Nasdaq (HOLX). The company generated approximately $3.9 billion in revenues for fiscal year 2024 (ending September 28) under CEO Stephen MacMillan, who has led Hologic since 2013 and transformed it from a single-product mammography company into a diversified women's health platform. Hologic's four business segments serve distinct clinical needs: Diagnostics (Panther molecular testing platform, cervical health testing, and COVID-19 diagnostics), Breast Health (3D mammography, breast biopsy guidance systems, radiation therapy), Surgical (NovaSure endometrial ablation, MyoSure fibroid removal, and minimally invasive hysteroscopy), and Skeletal Health (bone density measurement).

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

77
Overall Score
80
#53
Category Rank
#18
82
AI Consensus
83
stable
Trend
stable
78
ChatGPT
78
75
Perplexity
78
77
Gemini
80
82
Claude
84
75
Grok
77

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.